Skip to content
Livmarli(maralixibat chloride)
Livmarli (maralixibat chloride) is a small molecule pharmaceutical. Maralixibat chloride was first approved as Livmarli on 2021-09-29. It is used to treat pruritus in the USA. It has been approved in Europe to treat alagille syndrome. It is known to target ileal sodium/bile acid cotransporter.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
digestive system diseasesD004066
cardiovascular diseasesD002318
hereditary congenital and neonatal diseases and abnormalitiesD009358
skin and connective tissue diseasesD017437
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Livmarli
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Maralixibat chloride
Tradename
Company
Number
Date
Products
LIVMARLIMirum PharmaceuticalsN-214662 RX2021-09-29
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
livmarliNew Drug Application2022-04-05
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
pruritusHP_0000989D011537L29
Agency Specific
FDA
EMA
Expiration
Code
MARALIXIBAT CHLORIDE, LIVMARLI, MIRUM
2030-03-13ODE-429
2028-09-29ODE-379
2026-09-29NCE
2026-03-13NPP
Patent Expiration
Patent
Expires
Flag
FDA Information
Maralixibat Chloride, Livmarli, Mirum
112296472040-02-12U-3290
114977452040-02-12U-3290
113762512032-10-26U-3290
112600532031-05-26U-3290
ATC Codes
A: Alimentary tract and metabolism drugs
— A05: Bile and liver therapy drugs
— A05A: Bile therapy drugs
— A05AX: Other drugs for bile therapy in atc
— A05AX04: Maralixibat chloride
HCPCS
No data
Clinical
Clinical Trials
9 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Alagille syndromeD016738Q44.7—5———5
Biliary liver cirrhosisD008105K74.3—2———2
Sclerosing cholangitisD015209EFO_0004268K83.01—1———1
Intrahepatic cholestasisD002780—1———1
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameMARALIXIBAT CHLORIDE
INNmaralixibat chloride
Description
Maralixibat chloride, sold under the brand name Livmarli, is a medication used to treat cholestatic pruritus in people with Alagille syndrome. Maralixibat chloride is an ileal bile acid transporter (IBAT) inhibitor.
Classification
Small molecule
Drug classileal bile acid transporter (IBAT) inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCCCC1(CCCC)CS(=O)(=O)c2ccc(N(C)C)cc2[C@@H](c2ccc(OCc3ccc(C[N+]45CCN(CC4)CC5)cc3)cc2)[C@H]1O.[Cl-]
Identifiers
PDB—
CAS-ID228113-66-4
RxCUI—
ChEMBL IDCHEMBL17879
ChEBI ID—
PubChem CID9831642
DrugBankDB16226
UNII IDV78M04F0XC (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
SLC10A2
SLC10A2
Organism
Homo sapiens
Gene name
SLC10A2
Gene synonyms
ASBT, ISBT, NTCP2
NCBI Gene ID
6555
Protein name
ileal sodium/bile acid cotransporter
Protein synonyms
Apical sodium-dependent bile acid transporter, ASBT, IBAT, ileal apical sodium-dependent bile acid transporter, ileal bile acid transporter, Ileal Na(+)/bile acid cotransporter, Ileal sodium-dependent bile acid transporter, ISBT, Na(+)-dependent ileal bile acid transporter, Na+/taurocholate cotransporting polypeptide 2, Sodium/taurocholate cotransporting polypeptide, ileal, solute carrier family 10 (sodium/bile acid cotransporter family), member 2, solute carrier family 10 (sodium/bile acid cotransporter), member 2, Solute carrier family 10 member 2
Uniprot ID
Q13839
Mouse ortholog
Slc10a2 (20494)
ileal sodium/bile acid cotransporter (Q925U7)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 3 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details